« Previous
Next »
Titles
- E11(R1) addendum: clinical investigation of medicinal products in the pediatric population1
- E17 general principles for planning and design of multiregional clinical trials1
- E18 genomic sampling and management of genomic data1
- E6(R2) good clinical practice: integrated addendum to ICH E6(R1)1
- Elagolix for treating endometriosis: final evidence report1
- Electronic health information: CMS oversight of Medicare beneficiary data security needs improvement : report to Congressional requesters1
- Electronic health record adoption and interoperability among U.S. skilled nursing facilities and home health agencies in 20171
- Electronic health records: clear definition of the Interagency Program Office's role in VA's new modernization effort would strengthen accountability : testimony before the Subcommittee on Technology Modernization, Committee on Veterans' Affairs, House of Representatives1
- Elemental impurities in drug products1
- Eliminating the ACA's individual mandate: how would California fare?1
- Emergency communications: Office of Emergency Communication should take steps to help improve external communication : report to Congressional committees1
- Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report1
- Enabling sustainable investment in social interventions: a review of Medicaid managed care rate-setting tools1
- Encouraging edge science through NIH funding practices1
- Energy employees compensation: labor could better assist claimants through clearer communication : report to Congressional requesters1
- Enforcement policy--OTC sunscreen drug products marketed without an approved application1
- Ensuring health plan mergers benefit the community: California regulators and infrastructure investment programs1
- Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness1
- Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC1
- Establishing effectiveness for drugs intended to treat male hypogonadotropic hypogonadism attributed to nonstructural disorders1